NCT00189670View on ClinicalTrials.gov

Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Node Positive Breast Cancer
Interventions
PROCEDURE

6 TEC q 3 weeks

PROCEDURE

4 EC q 2 weeks followed by 4 TXT q 2 weeks

PROCEDURE

4 TXT q 2 weeks followed by 4 EC q 2 weeks

Sponsors
All Listed Sponsors
collaborator

Aventis Pharmaceuticals

INDUSTRY

collaborator

Amgen

INDUSTRY

lead

Association Européenne de Recherche en Oncologie

OTHER

NCT00189670 - Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer | Biotech Hunter | Biotech Hunter